The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
Open accessAbstract
BACKGROUND: Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint. METHODS: In a multicentre, 2×2 factorial, non-inferiority randomised trial, we enrolled adults aged at least 50 years with active, previously untreated neovascular age-related macular degeneration and a best corrected distance visual acuity (BCVA) of at least 25 letters from 23 hospitals in the UK. Participants were randomly assigned (1:1:1:1) to intravitreal injections of ranibizumab (0·5 mg) or bevacizumab (1·25 mg) in continuous (every month) or discontinuous (as needed) regimens, with monthly review. Study participants and clinical assessors were masked to drug allocation. Allocation to continuous or discontinuous treatment was masked up to 3 months, at which point investigators and participants were unmasked. The primary outcome was BCVA at 2 years, with a prespecified non-inferiority limit of 3·5 letters. The primary safety outcome was arterial thrombotic event or hospital admission for heart failure. Analyses were by modified intention to treat. This trial is registered, number ISRCTN92166560. FINDINGS: Between March 27, 2008, and Oct 15, 2010, 628 patients underwent randomisation. 18 were withdrawn; 610 received study drugs (314 ranibizumab; 296 bevacizumab) and were included in analyses. 525 participants reached the visit at 2 years: 134 ranibizumab in continuous regimen, 137 ranibizumab in discontinuous regimen, 127 bevacizumab in continuous regimen, and 127 bevacizumab in discontinuous regimen. For BCVA, bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference -1·37 letters, 95% CI -3·75 to 1·01; p=0·26). Discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1·63 letters, -4·01 to 0·75; p=0·18). Frequency of arterial thrombotic events or hospital admission for heart failure did not differ between groups given ranibizumab (20 [6%] of 314 participants) and bevacizumab (12 [4%] of 296; odds ratio [OR] 1·69, 95% CI 0·80-3·57; p=0·16), or those given continuous (12 [4%] of 308) and discontinuous treatment (20 [7%] of 302; 0·56, 0·27-1·19; p=0·13). Mortality was lower with continuous than discontinuous treatment (OR 0·47, 95% CI 0·22-1·03; p=0·05), but did not differ by drug group (0·96, 0·46-2·02; p=0·91). INTERPRETATION: Ranibizumab and bevacizumab have similar efficacy. Reduction in the frequency of retreatment resulted in a small loss of efficacy irrespective of drug. Safety was worse when treatment was administered discontinuously. These findings highlight that the choice of anti-VEGF treatment strategy is less straightforward than previously thought. FUNDING: UK National Institute for Health Research Health Technology Assessment programme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, in the IVAN study, the incidence was similar in eyes treated with ranibizumab (28%) and with bevacizumab (31%; p=0.46)”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In CATT and all randomized clinical trials of anti-VEGF treatment for neovascular AMD, most of the improvement in mean visual acuity from baseline occurred within the first 3 to 6 months with little erosion of the benefit through 2 years when a fixed schedule of monthly (ranibizumab, bevacizumab, aflibercept) or bi-monthly (aflibercept) treatment was maintained.1,7,9,17,34”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“decreasing the likelihood of a true effect of ranibizumab on development of geographic atrophy.”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
In the citing paper
“In the IVAN study, 34% of eyes that received continuous (monthly) treatment developed geographic atrophy as compared with 26% in the discontinuous (PRN) group (p=0.03).9”
From Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration (2016) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 4,204
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
New Visual Acuity Charts for Clinical Research
Ferris, F. L., Kassoff, A., Bresnick, G. H., & Bailey, I. L. (1982) · American Journal of Ophthalmology · doi:10.1016/0002-9394(82)90197-0 · Cited by 2,147
Cited by
Sorted by citations
Items 601–700 of 743
Dorrans, B., & Llano, A. (2020) · Practical Diabetes · doi:10.1002/pdi.2268 · Cited by 2
Stewart, M. W. (2016) · EMJ Diabetes · doi:10.33590/emjdiabet/10310409 · Cited by 2
Angiogenesis-Based Therapies for Eye Diseases
Patil, R. V., Wong, C. W., Michelet, F., Teo, K. Y. C., Ting, D. S. W., Tsai, A. S. H., Cheung, C. M. G., & Wong, T. Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-61115-0_12 · Cited by 2
Yu, S., Rückert, R., & Munk, M. R. (2019) · Expert Review of Ophthalmology · doi:10.1080/17469899.2019.1698948 · Cited by 2
“Although 2-year results of CATT and IVAN study showed that reduced retreatment frequency in a PRN regimen resulted in a small loss of efficacy [13,14], PRN regimen became the predominantly used regimen in the next years.”
ResultStahl, A., Hellström, A., & Smith, L. E. H. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_2 · Cited by 2
Targeted Management of Excess Specialty Spending: The Case of Biologics for Retinal Disease
Moon, H., Mitton, J. A., Redmond, A., & Stine, N. W. (2022) · NEJM Catalyst · doi:10.1056/cat.21.0375 · Cited by 1
Daruwalla, C., Andrieni, J., Hsu, E., Uzair, S. A., Wykoff, C. C., & Lee, A. G. (2023) · Retina · doi:10.1097/iae.0000000000003679 · Cited by 1
Begaj, T., Jeong, D., Park, J. G., Runner, M. M., Capone, A., Dass, A. B., Drenser, K. A., Faia, L. J., Farley, N. D., Garretson, B. R., et al. (2023) · Retina · doi:10.1097/iae.0000000000003961 · Cited by 1
“15,16 However, our data suggest that frequency of anti-VEGF injections is not solely responsible as our cohort had a similar injection frequency throughout the study period.”
BackgroundNakanishi, K., Takamura, Y., Nakano, Y., Inatani, M., & Oki, M. (2025) · Genes to Cells · doi:10.1111/gtc.13196 · Cited by 1
Pharmacovigilance in intraocular antiangiogenic therapy
Shahsuvaryan, M. L. (2025) · Cutaneous and Ocular Toxicology · doi:10.1080/15569527.2025.2475445 · Cited by 1
Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease
Reddy, A., Greene, C., Hashimoto, Y., Kiang, A., Hudson, N., Adamson, P., Santos‐Ferreira, T., & Campbell, M. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101450 · Cited by 1
Teper, S. J., Ledwoń, D. J., Sendecki, A., Romaniszyn‐Kania, P., Tuszy, A., Nycz, J., Mitas, A. W., Figurska, M., Wylęgała, E., & Rękas, M. (2025) · Acta Ophthalmologica · doi:10.1111/aos.70040 · Cited by 1
“However, outcomes observed in randomized controlled trials may not fully reflect real-world effectiveness due to strict inclusion criteria and controlled settings (Chakravarthy et al., 2013).”
Mhmud, H., Vermeulen, J., Adanç, B., Klevering, J., Groenink-Lindenhovius, C., Tigchelaar-Besling, O. A. M., Ponsioen, T. L., Klaver, C. C. W., & Witmer, A. N. (2026) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-07082-3 · Cited by 1
“…burden associated with bevacizumab may partly be attributed to its lower efficacy in achieving anatomical fluid resolution on OCT, as demonstrated in head-to-head clinical trials, potentially prompting clinicians to administer injections more frequently to maintain disease control [6 , 7 ].”
Sadeghi, E., DeCicco, J., Gandhi, P., Hasan, N., DiCenzo, B., Jiang, J. Y., Rahmanipour, E., Sahel, J., Eller, A. W., & Chhablani, J. K. (2026) · Eye · doi:10.1038/s41433-026-04331-5 · Cited by 1
“This association is further supported by findings from the CATT [26] and IVAN [27] trials.”
Contreras-Salinas, H., Vázquez-Beltrán, J. C., García-Sánchez, G., Quirarte-Justo, S., Macías, S. D. C. G., & Rodríguez-Herrera, L. Y. (2026) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986261462682 · Cited by 1
“…; although the IVAN trial observed more athero-thrombotic events and heart failure in the bevaci-zumab group, this was not statistically significant 60 ; likewise the meta-analysis by Virgili et al. 61 did not identify significant differences in the incidence of serious AEs across anti-VEGF…”
Aflibercept for diabetic macular edema
Udaondo, P., Delpech, S. G., Matinez-Costa, R., Piera, J. N., & Cisneros-Lanuza, Á. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.931809 · Cited by 1
Choroidal neovascularization secondary to pathological myopia
Teo, K. Y. C. (2014) · World Journal of Ophthalmology · doi:10.5318/wjo.v4.i3.35 · Cited by 1
Recent Advances in Topical Therapeutics for Vitreoretinal Diseases
Gibson, J. M., & McGinnigle, S. (2015) · touchREVIEWS in Ophthalmology · doi:10.17925/usor.2015.8.1.60 · Cited by 1
The Future of Treatment for Wet AMD
Desai, S. J., & Reichel, E. (2017) · Current Ophthalmology Reports · doi:10.1007/s40135-017-0125-4 · Cited by 1
Autologous Bone Marrow-Derived Cell Therapies for Retinal Disease
Moisseiev, E., & Park, S. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-49479-1_7 · Cited by 1
Intravitreal aflibercept: its role in treatment of neovascular age-related macular degeneration
Cundy, O., Shah, M., & Downes, S. M. (2018) · Expert Review of Ophthalmology · doi:10.1080/17469899.2018.1468250 · Cited by 1
“Although there was no statistical difference in best-corrected visual acuity (BCVA) between continuous monthly and as-needed treatment groups in the IVAN trial at two years, two-year results of the CATT trial favored monthly treatment [58].”
BackgroundMethodSelf-citationChhablani, J. K., Singh, S., Parikh, R., Sakurada, Y., Uplanchiwar, B., Mansour, A. M., Goud, A., & Modi, Y. (2020) · Taiwan Journal of Ophthalmology · doi:10.4103/tjo.tjo_3_20 · Cited by 1
Erba, S., Scialdone, A., & Casalino, G. (2020) · Medical Hypothesis Discovery & Innovation in Ophthalmology · doi:10.51329/mehdiophthal1404 · Cited by 1
“Several randomized controlled trials (RCTs) such as the Comparison of Age-related macular degeneration Treatments Trials (CATT) study and the alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularization (IVAN) study, have demonstrated that bevacizumab is not inferior to ranibizumab in the treatme…”
BackgroundJia, H., Li, T., Wan, H., Wu, Z., & Sun, X. (2022) · Retina · doi:10.1097/iae.0000000000003649 · Cited by 1
Foster, M. J., Shaia, J. K., Maatouk, C. M., Urbano, C. A., Bui, M. T., Hom, G. L., Kuo, B. L., Singh, R. P., & Talcott, K. E. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230223-01 · Cited by 1
Cost awareness amongst irish ophthalmologists
Power, B. J. (2023) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-023-03332-7 · Cited by 1
“There are a small number of conditions that may respond better to the more expensive Aflibercept and Ranabizumab, but the generic drug Avas-tin has been shown in multiple trials to be non-inferior in treatment of AMD and retinal vein occlusions associated with macular oedema [13–15].”
BackgroundBorodic, G. E. (2023) · Toxicon · doi:10.1016/j.toxicon.2023.107170 · Cited by 1
Song, L., Luo, C.-Y., Zheng, Y., & Sha, X. (2023) · International Ophthalmology · doi:10.1007/s10792-023-02655-9 · Cited by 1
“(1234567890) injection is not only associated with the development of geographic atrophy of macular region, but also increase the risk of endophthalmitis and ocular complications [21, 22].”
BackgroundLong term follow up of patients with MNV3 treated with intra-vitreal Aflibercept
Browning, A. C., Grinton, M. E., Quinn, S. A., Jain, T., Manikavasagar, V., & Aftab, A. M. (2024) · European Journal of Ophthalmology · doi:10.1177/11206721241229912 · Cited by 1
“…whether anti-VEGF agents stimulated the formation of macular atrophy 4,14,15,27 and so because MNV3 was recognised as a risk factor for MA it was decided to change from the capped prn model of treatment, in which treatment was mandated at least every 12 weeks, to a prn regimen for years 4 and 5.”
Schoumacher, M., Lambert, V., Campas, M., Blaise, P., Locht, B., Thys, M., Duchateau, E., Cavalier, E., Rakic, J., Noël, A., et al. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1449226 · Cited by 1
Bianco, L., Audo, I. S., Antropoli, A., Jeffery, R. C. H., Chen, F. K., Arrigo, A., Mansour, A. M., Zeitz, C., Bandello, F. M., & Parodi, M. B. (2025) · Retina · doi:10.1097/iae.0000000000004476 · Cited by 1
Viggiano, P., Santoro, M. C., Boscia, G., Porreca, A., Borrelli, E., Bacherini, D., Lombardi, L., Fumarola, R., Grassi, M. O., Termite, A. C., et al. (2025) · Acta Ophthalmologica · doi:10.1111/aos.17502 · Cited by 1
Cost-effectiveness of intravitreal therapy in Age-Related Macular Degeneration
Neri, P., Arapi, I., Eandi, C. M., Pirani, V., Mariotti, C., & Giovannini, A. (2014) · Farmeconomia Health economics and therapeutic pathways · doi:10.7175/fe.v15i4.976 · Cited by 1
Chiam, P. J. T., Ho, V. W. M., Hickley, N. M., & Kotamarthi, V. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.04.12 · Cited by 1
Neovascular age-related macular degeneration in Austria
TargetAMD Group, STOLBA, U., Ansari‐Shahrezaei, S., Hagen, S., Stattin, M., Schmid, S., Kropp, M., Harmening, N., & Thumann, G. (2017) · Spektrum der Augenheilkunde · doi:10.1007/s00717-017-0356-7 · Cited by 1
“3% of patients after 2 years, while this number increased to 30% in the IVAN study [22].”
BackgroundEssex, R. W., Nguyen, V., Daïen, V., Steinmann, S., Walton, R., Gillies, M. C., & Barthelmes, D. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-311852 · Cited by 1
Chaili, S., & Adrean, S. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81466 · Cited by 1
Kaya, C., Pfister, I. B., Gerhardt, C., & Garweg, J. G. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04667-y · Cited by 1
Health Promotion, Audit, Research and Evidence-Based Medicine
Fung, T. H. M., & Amoaku, W. M. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-43063-4_5 · Cited by 1
Ruamviboonsuk, P., Chotcomwonse, P., Nganthavee, V., Pattanapongpaiboon, W., & Hemarat, K. (2020) · Springer eBooks · doi:10.1007/978-981-15-2213-0_20 · Cited by 1
Glück, S., Brandlhuber, U., Gerbutavicius, R., Kortüm, G. ‐., Kortüm, I., Orozco, R. N., Rakitin, M., Strodtbeck, M., & Kortuem, K. (2020) · Der Ophthalmologe · doi:10.1007/s00347-020-01267-3 · Cited by 1
Transient Ischemic Attack and Hypoventilation 12 Hours After Intra-vitreal Aflibercept Injection
Hamadneh, T., Shehadeh, M. H., Yasin, A., Akkawi, M., An, M., Yamin, H. S., & Azamtta, M. (2021) · Cureus · doi:10.7759/cureus.13488 · Cited by 1
“For instance, a 2-year data from the IVAN trial showed a statistically significant higher risk of cardiovascular events with bevacizumab than with ranibizumab [15].”
BackgroundSangroongruangsri, S., Chaikledkaew, U., Hanusaha, P., Ratanapakorn, T., & Ruamviboonsuk, P. (2021) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s340570 · Cited by 1
Fung, T. H. M., & Amoaku, W. M. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-43063-4_10 · Cited by 1
Chong, E. W. T., & Al‐Qureshi, S. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12968 · Cited by 1
Bevacizumab: a new way of doing business. Part 2
Lotery, A. J., & Burdon, M. (2018) · Eye · doi:10.1038/s41433-018-0281-2 · Cited by 1
Self-citationChakravarthy, U. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.01.016 · Cited by 1
Self-citationPrédiction du risque de DMLA : identification de nouveaux biomarqueurs et modélisation du risque
Ajana, S. (2019) · theses.fr (ABES) · doi:10.70675/b0924b67ze4edz4545za9c7zf7fba3f23057 · Cited by 1
Stewart, M. W. (2015) · Clinical ophthalmology · doi:10.2147/opth.s89831
Conti, V., Venegoni, M., Moretti, U., & Barbui, C. (2015) · Europe PMC (PubMed Central) · doi:10.3980/j.issn.2222-3959.2015.01.35
Chakravarthy, U., & Czeszynski, A. D. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.910455
Self-citationBevacizumab must be specially prepared for intraocular use
Georgalas, I., Papaconstantinou, D., Paraskevopoulos, T., & Koutsandrea, C. (2013) · BMJ · doi:10.1136/bmj.f5032
Johnson, D. E., Jagan, L., Kurji, A., Jumaa, K. B., & Sharma, S. (2014) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.08.018
Mans, D. R. A. (2015) · International Archives of Medicine · doi:10.3823/1730
Retinal oximetry and age-related macular degeneration
Geirsdóttir, Á. (2015) · Skemman
Ribeiro, S. D. V. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/grjv-me24
Context for Protons as Adjunctive Therapy in Neovascular Age-Related Macular Degeneration: A Review
Rice, S. R., Katz, M. S. J., & Mehta, M. P. (2016) · International Journal of Particle Therapy · doi:10.14338/ijpt-15-00019.1
“The US Comparisons of AMD Treatments (CATT) [28, 29] and the UK Inhibition of VEGF in Age-Related CNV (IVAN) trials [30, 31] were head-to-head comparisons of intravitreal bevacizumab and ranibizumab that showed noninferiority of bevacizumab and have supported off-label use of bevacizumab for AMD as a cost-effective al…”
BackgroundMethodNg, D. S., Kwok, A. K., Tong, J. M.-K., Chan, C. W.-N., & Li, W. W.-T. (2016) · International Journal of Ophthalmology · doi:10.18240/ijo.2016.03.17
The Controversies Surrounding Bevacizumab and Ranibizumab
Low, E. V., & Yusof, F. A. M. (2014) · Advances in Research · doi:10.9734/air/2015/13322
“The major trials are Comparison of age related macular degeneration treatment trials (CATT) funded by National Eye Institute in the USA [5,6], the inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial by UK National Institute for Health Research (NIHR) Health Technology Assessment Programme [7,8]…”
[Cultivation of pathogenic free-living amoebae].
Heng, P., & Zhu, H.-M. (2009) · PubMed
Fuzzard, D. R. W., Guymer, R. H., & Finger, R. P. (2016) · Essentials in ophthalmology/Essentials ophthalmology · doi:10.1007/978-3-319-24097-8_3
The Evidence Supporting Ranibizumab in the Treatment of Neovascular Age-related Macular Degeneration
Kelly, S. P., & Amoaku, W. M. K. (2013) · European Ophthalmic Review · doi:10.17925/eor.2013.07.02.102
Thalgott, V., Feucht, N., Lohmann, C. P., & Maier, M. M. (2016) · Der Ophthalmologe
Ranibizumab in Treatment for Age-related Macular Degeneration
Araiz, J., Arias, L., García‐Layana, A., Ruiz‐Moreno, J. M., & Instituto Clínico Quirúrgico de Oftalmología (ICQO), B. (2013) · European Ophthalmic Review · doi:10.17925/eor.2013.07.02.109
Stewart, M. W. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1243094
Clinical evaluation of mechanism of precipitate labor
Евгеньевна, Ж. М., Malceva, L. I., & Зефирова, Т. П. (2016) · Kazan medical journal · doi:10.17750/kmj2016-709
Gaybaryan, R. V., Epikhin, A. N., & Bondarenko, Y. F. (2016) · Kazan medical journal · doi:10.17750/kmj2016-705
“Ряд клинических исследований продемонстрировал практически одинаковую эффективность ранибизумаба и бевацизумаба при лечении влажной ВМД [6, 9].”
Knippschild, S., Krummenauer, F., & Baulig, C. (2016) · International Journal of Advanced Research · doi:10.21474/ijar01/2600
“…(Arias et al., 2006, Azab et al., 2005, Beatty et al., 2013, Boyer et al., 2009, Bressler et al., 2004, Brown et al., 2009, Busbee et al., 2013, Chakravarthy et al. 2013, Chang et al., 2010, Chaudhary et al., 2007, Comparison of Age-related Macular Degeneration Treatments Trials Research et…”
BackgroundMethodInfluentialGrüb, M., Lamprakis, I., & Reichel, C. (2017) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0043-118099
Thurman, S. M., Maniglia, M., Davey, P. G., Biles, M. K., Visscher, K., & Seitz, A. R. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.5.28
“Indeed, recent studies have shown that timely interventions can be critically important in these patients, 21 with new drugs available that can prevent further vision loss 21–24 and improve vision in approximately one-third of MD patients.”
Queguiner, F., Bezirganyan, K., Gensollen, S., Curel, L., Raffray, M., Pénaranda, G., & Righini, M. (2018) · New Frontiers in Ophthalmology · doi:10.15761/nfo.1000206
“Anti-vascular endothelial growth factors (VEGF) were the first medications that improved visual acuity (VA) [4-16] and are now considered as standard treatment for AMD.”
BackgroundFailure to Complete Induction in Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration
Hanhart, J., Comaneshter, D. S., & Vinker, S. (2018) · International Journal of Ophthalmology and Clinical Research · doi:10.23937/2378-346x/1410101
“Ranibizumab [2-14], bevacizumab [2,4,8,9,11,12,15] and more recently aflibercept [16] have all been extensively studied in large, multicenter, double-masked, prospective studies.”
BackgroundResultFoucault‐Fruchard, L., Watier, H., & Antier, D. (2019) · médecine/sciences · doi:10.1051/medsci/2019212
THE SUCCESS OF INTRAVITREAL INJECTIONS.
O’Donnell, M., & Williams, M. (2017) · Europe PMC (PubMed Central)
Stasch-Bouws, J., Eller-Woywod, S. M., Schmickler, S., Inderfurth, J., Hoffmann, P., Ohlmeyer, C., Kammering, B., & Pauleikhoff, D. (2020) · Der Ophthalmologe
Bianchi, L. C. D. S. N., Vieira, L. T. Q., Isaac, D. L. C., & de Ávila, M. P. (2020) · Brazilian Journal of Development · doi:10.34117/bjdv6n9-062
ASSISTÊNCIA INTEGRAL: CONDUTAS PROFILÁTICAS E TERAPÊUTICAS EM GESTANTES COM ANEMIA FALCIFORME
Chaves, M. P., do Nascimento, N. R., Dornelas, M. A. D. M., de Godoy, A. A. R., & de Freitas, M. A. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000892
AUMENTO DE COROA CLÍNICA ESTÉTICA SUPERIOR
Dias, K. S. P. A., Silva, I. C. M., Rocha, C. R., & Freitas, H. E. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000896
ASTROCITOMA PILOCÍTICO CEREBELAR DE DESENVOLVIMENTO ATÍPICO: RELATO DE CASO
Ribeiro, L. M., Linhalis, B. S., Ferreira, K. D. M., de Souza, P. G. K., & Lee, S. Y. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000916
COLANGIOCARCINOMA AVANÇADO: UM RELATO DE CASO
Chixaro, J. D. O., de Oliveira, L. P., Colares, W. T. H. C., de Andrade, B. B., Santana, Y. M., Filho, K. P. D. O., & Cortez, M. V. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000917
Maia, M. R., & Celeste, L. E. N. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000911
O PAPEL DO ENFERMEIRO NA PREVENÇÃO DE INFECÇÃO NO SÍTIO CIRÚRGICO
Lauria, T. A. L. F., de Souza, M. T., de Oliveira, C. R. M., de Freitas, A. H., & Freitas, S. C. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000900
IMUNOTERAPIA NA DOENÇA DE HUNTINGTON: UMA REVISÃO SISTEMÁTIC
Martin, R. R. H., Gontijo, B. D. A. V., Guimarães, J. D. S., Toledo, R. G., Patricio, B. M. K., Verde, L. D. A. L. V., de Mesquita, H. L., Sousa, A. L., & Guimarães, L. C. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000903
Bianchi, L. C. D. S. N., Vieira, L. T. Q., Isaac, D. L. C., & de Ávila, M. P. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000904
LESÃO DE QUADRIL PREDOMINANTE EM TENISTAS: REVISÃO SISTEMÁTICA
Santos, J. V. D. S., do Nascimento, D. A., dos Santos, E. F., de Oliveira, É. M. P., da Silva, V. B., Bosnic, F., Falconi, C. A., & Doro, M. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000910
Ellis, L. A. (2016) · http://isrctn.com/ · doi:10.1186/isrctn92746680
Camilo, L. D. L., da Silva, K. R., Galvão, C. A. L., Lazzareschi, L., Lima, S. C. D. C. R., da Silva, A., & Filoni, E. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000907
de Deus, M. H. A., Martins, J. M., Júnior, G. D., & Orsolin, P. C. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0000908
USO TERAPÊUTICO DA MACONHA EM PACIENTES COM GLAUCOMA: UMA REVISÃO
Pinto, J. T. T., Menegucci, G., Borini, P., & Pinto, F. T. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000901
da Silva, V. J., & de Alencar, J. L. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000906
EFETIVIDADE DA EMDR NO TRATAMENTO DO TRANSTORNO DE ESTRESSE PÓS-TRAUMÁTICO: UMA REVISÃO INTEGRATIVA
Izotton, T. W., Báo, I., Zancanaro, M., & Sachser, R. M. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000902
ANÁLISE DOS IMPACTOS DA COVID-19 NO TRANSPLANTE HEPÁTICO
Feu, N. B., Bicalho, J. A. R., da Silva, E. R. T., Caprini, M. D., & Pacheco, M. P. (2021) · EDILSON ANTONIO CATAPAN eBooks · doi:10.35587/brj.ed.0000914
Stem cells perspective in cure and management of diabetic retinopathy
Batool, L. (2021) · Pure and Applied Biology · doi:10.19045/bspab.2021.100147
Terapias Presentes y Futuras para tratar Degeneración Macular Relacionada con la Edad
Kamal, A., Khan, M. A., Agarwal, K., & Loutfi, M. (2015) · Highlights of Ophthalmology · doi:10.5005/hos-10101-43404
Pharmacotherapy of Age-Related Macular Degeneration
Laíns, I., Kim, I. K., & Husain, D. (2021) · Springer eBooks · doi:10.1007/978-3-319-90495-5_112-1
Tratamento com Anti-VEGF e Atrofia Macular: Uma Revisão
Tavares, S. D. O. F., Damasceno, M. D. L. B. C., & da Silva, R. M. (2021) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.48560/rspo.23900
Loewenstein, A., & Keenan, T. D. L. (2021) · Expert Review of Ophthalmology · doi:10.1080/17469899.2021.1990757
“Also, some studies have shown an association between PRN treatment and inferior visual outcomes [15,19,20].”
BackgroundStem cells perspective in cure and management of diabetic retinopathy
Batool, L. (2021) · Pure and Applied Biology · doi:10.19045/bspab.2021-100147
Metadata
- Authors
- Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Chakravarthy, Usha
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 382
- Issue
- 9900
- Pages
- 1258-1267
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2154073405
- Cited by
- 748
- References
- 45
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 36 · 2023: 36 · 2022: 33 · 2021: 84 · 2020: 66 · 2019: 44 · 2018: 74 · 2017: 66 · 2016: 90 · 2015: 77 · 2014: 75 · 2013: 13
- FWCI
- 84.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, cc-by-nc-sa)
- Bristol Research (University of Bristol) (submittedVersion, cc-by-nc-sa)
- ePrints Soton (University of Southampton) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institute for Health and Care Research (07/36/01)
- Health Technology Assessment Programme (07/36/01, /36/01)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, choroidal neovascularization, bevacizumab, ranibizumab, anti-VEGF therapy, intravitreal injection, treatment regimen comparison, best-corrected visual acuity, non-inferiority, arterial thrombotic events, long-term outcomes
- MeSH terms
- Bevacizumab, Ranibizumab, Aged, Female, Humans, Male, Middle Aged, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
